These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prevalence of Epstein-Barr Virus Infection and Mismatch Repair Protein Deficiency and the Correlation of Immune Markers in Tibetan Patients with Gastric Cancer. Shi J; Yang X; Wang X; Luo Y; Zhou W; Luo H; Bianba Z; Nima Z; Wang Q; Wang H; Liao R; Ciren Q; Li M; Pang J Biomed Res Int; 2022; 2022():2684065. PubMed ID: 35734348 [TBL] [Abstract][Full Text] [Related]
6. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Lee LH; Cavalcanti MS; Segal NH; Hechtman JF; Weiser MR; Smith JJ; Garcia-Aguilar J; Sadot E; Ntiamoah P; Markowitz AJ; Shike M; Stadler ZK; Vakiani E; Klimstra DS; Shia J Mod Pathol; 2016 Nov; 29(11):1433-1442. PubMed ID: 27443512 [TBL] [Abstract][Full Text] [Related]
7. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy. Wu F; Jiang T; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Bai X; Ren S; Zhou C; Cancer Commun (Lond); 2022 Dec; 42(12):1331-1346. PubMed ID: 36331328 [TBL] [Abstract][Full Text] [Related]
8. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1. Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513 [TBL] [Abstract][Full Text] [Related]
9. Combined prognostic value of CD274 (PD-L1)/PDCDI (PD-1) expression and immune cell infiltration in colorectal cancer as per mismatch repair status. Ahtiainen M; Wirta EV; Kuopio T; Seppälä T; Rantala J; Mecklin JP; Böhm J Mod Pathol; 2019 Jun; 32(6):866-883. PubMed ID: 30723299 [TBL] [Abstract][Full Text] [Related]
10. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers of Pathologic Complete Response to Neoadjuvant Immunotherapy in Mismatch Repair-Deficient Colorectal Cancer. Li J; Hu H; Qin G; Bai F; Wu X; Ke H; Zhang J; Xie Y; Wu Z; Fu Y; Zheng H; Gong L; Xie Z; Deng Y Clin Cancer Res; 2024 Jan; 30(2):368-378. PubMed ID: 37906636 [TBL] [Abstract][Full Text] [Related]
12. Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study. Cheng YK; Chen DW; Chen P; He X; Li PS; Lin ZS; Chen SX; Ye SB; Lan P Front Immunol; 2022; 13():809971. PubMed ID: 35185898 [TBL] [Abstract][Full Text] [Related]
13. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors. Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238 [TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
15. Programmed death-ligand 1 expression in the immune compartment of colon carcinoma. Yılmaz O; Pankaj A; Neyez A; Rickelt S; Taylor M; Lang ER; Leijsen L; Dinaux A; Shroff SG; Crotty R; Zhang ML; Cerda S; Zhao Q; Ferrone C; Ting DT; Patil DT; Yilmaz O; Berger D; Deshpande V Mod Pathol; 2022 Nov; 35(11):1740-1748. PubMed ID: 35773332 [TBL] [Abstract][Full Text] [Related]
16. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918 [TBL] [Abstract][Full Text] [Related]
17. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy. Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821 [TBL] [Abstract][Full Text] [Related]
18. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients. López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332 [TBL] [Abstract][Full Text] [Related]
19. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
20. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups. Kir G; Olgun ZC; Soylemez T; Aydin A; Demircan B; Kaya IA; McCluggage WG Int J Gynecol Pathol; 2021 Nov; 40(6):575-586. PubMed ID: 33332859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]